The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

Xeris has three commercially available products: Recorlev, for the treatment of endogenous Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment ... and BP1001-A, a drug product ...

Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...